Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Indoles
  • Interferon-alpha
  • Kidney Neoplasms
  • Protein Kinase Inhibitors
  • Pyrroles

abstract

  • Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).

publication date

  • January 11, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa065044

PubMed ID

  • 17215529

Additional Document Info

start page

  • 115

end page

  • 24

volume

  • 356

number

  • 2